The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: Low muscle mass and weakness are common and potentially disabling in older adults, but in order to become recognized as a clinical condition, criteria for diagnosis should be based on clinically relevant thresholds and independently validated. The Foundation for the National Institutes of Health Biomarkers Consortium Sarcopenia Project used an evidence-based approach to develop these criteria. Initial findings were presented at a conference in May 2012, which generated recommendations that guided additional analyses to determine final recommended criteria. Details of the Project and its findings are presented in four accompanying manuscripts. METHODS: The Foundation for the National Institutes of Health Sarcopenia Project used data from nine sources of community-dwelling older persons: Age, Gene/Environment Susceptibility-Reykjavik Study, Boston Puerto Rican Health Study, a series of six clinical trials, Framingham Heart Study, Health, Aging, and Body Composition, Invecchiare in Chianti, Osteoporotic Fractures in Men Study, Rancho Bernardo Study, and Study of Osteoporotic Fractures. Feedback from conference attendees was obtained via surveys and breakout groups. RESULTS: The pooled sample included 26,625 participants (57% women, mean age in men 75.2 [±6.1 SD] and in women 78.6 [±5.9] years). Conference attendees emphasized the importance of evaluating the influence of body mass on cutpoints. Based on the analyses presented in this series, the final recommended cutpoints for weakness are grip strength <26kg for men and <16kg for women, and for low lean mass, appendicular lean mass adjusted for body mass index <0.789 for men and <0.512 for women. CONCLUSIONS: These evidence-based cutpoints, based on a large and diverse population, may help identify participants for clinical trials and should be evaluated among populations with high rates of functional limitations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The separate criteria for muscle mass and strength implied the need to target interventions for individuals with low mass or low strength.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [182]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently, there is no international consensus on the operational definition of sarcopenia, and several definitions of sarcopenia are used with consequent impact on the prevalence of sarcopenia [6,[31][32][33][34].”
From Is There Enough Evidence for Osteosarcopenic Obesity as a Distinct Entity? A Critical Literature Review (2019) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, a major reason for the variation in sarcopenic obesity prevalence is the method of adjusting muscle quantity for body size.46,47,55,57”
From Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies (2024) · cites this paper as [57]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenia, a decrease in muscle mass and/or function, is frequent in undernourished patients admitted to the ICU [21].”
From ESPEN practical and partially revised guideline: Clinical nutrition in the intensive care unit (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Foundation for the National Institutes of Health (FNIH) Sarcopenia Project182 suggested a causal, indirect relationship between muscle mass and function in their definition of sarcopenia.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [182]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Gait speed and survival in older adults.
Studenski, S. (2011) · JAMA · doi:10.1001/jama.2010.1923 · Cited by 4,558 · cited 1×
“8 m/s because it predicts reduced overall survival (13), disability (14), and has been recommended by other experts (15).”
BackgroundSelf-citationEpidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004 · cited 1×
“The definition proposed for sarcopenia was a ratio of muscle mass to height 2 SDs below the mean found in healthy young persons drawn from the Rosetta Stone project (37).”
BackgroundFollow-up report on the diagnosis of diabetes mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2003) · Diabetes Care · doi:10.2337/diacare.26.11.3160 · Cited by 3,784
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Guralnik, J. M., Ferrucci, L., Pieper, C. F., Leveille, S. G., Markides, K. S., Ostir, G. V., Studenski, S., Berkman, L. F., & Wallace, R. B. (2000) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/55.4.m221 · Cited by 2,898 · cited 3×
“Walking courses that were longer or shorter were converted to a speed that would have been achieved on a 4- or 6-m course using previously published equations (33).”
BackgroundMethodInfluentialSelf-citationEpidemiological approaches to heart disease: the Framingham study
Dawber, T. R., Meadors, G. F., & Moore, F. E. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.3.279 · Cited by 2,148 · cited 1×
“—In 1948, the Framingham Heart Study (FHS) Original cohort recruited two thirds of the population sample from Framingham, Massachusetts, to evaluate risk factors of heart disease (24).”
BackgroundAbellan Van Kan, G., Rolland, Y., Andrieu, S., Bauer, J., Beauchet, O., Bonnefoy, M., Cesari, M., Donini, L. M., Gillette-Guyonnet, S., Inzitari, M., et al. (2009) · The Journal of nutrition, health and aging · doi:10.1007/s12603-009-0246-z · Cited by 2,003 · cited 1×
“8 m/s because it predicts reduced overall survival (13), disability (14), and has been recommended by other experts (15).”
Background
Cited by
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
“…kg Dodds (2014) [26] Chair stand >15 s for five rises Cesari (2009) [67] EWGSOP2 sarcopenia cut-off points for low muscle quantity ASM <20 kg <15 kg Studenski (2014) [3] ASM/height2 <7.0 kg/m2 <6.0 kg/m2 Gould (2014) [125] EWGSOP2 sarcopenia cut-off points for low performance Gait speed ≤0.8 m/s…”
BackgroundInfluentialCruz-Jentoft, A. J., & Sayer, A. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31138-9 · Cited by 3,905
Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., Baptista, G., Barazzoni, R., Blaauw, R., Coats, A., et al. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.08.002 · Cited by 3,022
“…of recommended cut-off values for muscle mass reductions, GLIM refers to recommendations from the European Working Group on Sarcopenia in Older People (EWGSOP) [15] and from The Foundation of National Institute of Health (FNIH) initiative [16], and the Asian Working Group on Sarcopenia (AWGS) [17].”
BackgroundMethodESPEN guideline on clinical nutrition in the intensive care unit.
Singer, P., Blaser, A. R., Berger, M. M., Alhazzani, W., Calder, P. C., Casaer, M. P., Hiesmayr, M., Mayer, K., Montejo, J. C., Pichard, C., et al. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.08.037 · Cited by 2,904
“Sarcopenia is defined as a decrease in muscle loss and/or function and is frequent in undernourished patients admitted to the ICU [27].”
Cederholm, T., Jensen, G. L., Correia, M. I. T. D., Gonzalez, M. C., Fukushima, R., Higashiguchi, T., Baptista, G., Barazzoni, R., Blaauw, R., Coats, A. J. S., et al. (2019) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12383 · Cited by 1,724
“Assessment of muscle strength should be an integral measure in assessment of patients with suspected sarcopenia since impairment of muscle strength is now recognized as a key component for diagnosis of sarcopenia.(15,16) Though inflammatory mediators and other mechanisms besides malnutrition are at play, it is recomme…”
Background
Metadata
- Authors
- Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., Kiel, D. P., Kritchevsky, S. B., Shardell, M. D., Dam, T.-T. L., & Vassileva, M. T.
- Affiliations
- University of Pittsburgh (US)
- California Pacific Medical Center (US)
- University of Maryland, Baltimore (US)
- Beth Israel Deaconess Medical Center (US)
- National Institutes of Health (US)
- University of Central Florida (US)
- Wake Forest University Health Sciences (US)
- Columbia University (US)
- Foundation for the National Institutes of Health (US)
- Corresponding author
- Studenski, Stephanie A.
- ORCID
- Venue
- The Journals of Gerontology: Series A
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-31
- Volume
- 69
- Issue
- 5
- Pages
- 547-558
- ISSN
- 1079-5006 (ISSN-L)
- 1758-535X
- PMC
- PMC3991146
- OpenAlex
- W2156791190
- Cited by
- 2,545
- References
- 41
- Citations by year
- 2026: 186 · 2025: 315 · 2024: 270 · 2023: 254 · 2022: 257 · 2021: 272 · 2020: 246 · 2019: 206 · 2018: 195 · 2017: 138 · 2016: 86 · 2015: 85 · 2014: 29
- FWCI
- 74.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- The Journals of Gerontology Series A (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Journal of International Crisis and Risk Communication Research (submittedVersion)
- Funders
- Foundation for the National Institutes of Health (N01‐HC 25195, N01-AG-12100, P30 AG024827)
- Patrick and Catherine Weldon Donaghue Medical Research Foundation
- Amgen
- Eli Lilly and Company
- Ministero della Salute (263 MD 9164 13, N01-AG-916413, 263 MD 821336, N01-AG-821336, 263 MD 9164)
- Syddansk Universitet
- Hjartavernd (N01-AG-1-2100)
- National Institutes of Health (N01-AG-6-2103, n01ag12100-57-0-2, N01-AG-916413, N01‐AG‐6‐2106, 263MD9164, 1u13ag041583-01, N01-AG-6-2101, n01hc25195-41-0-1, 263 MD 821336, N01-AG-821336, AR/AG41398)
- University of California, San Diego
- National Institute on Aging (N01‐AG‐6–2101, 263 MD 9164, R37AG007181, R01AG005394, N01AG-821336, DK31801, 263-MD-9164-13, 5P60AG13631, AG005407, 821336, 1U13AG041583, N01[AG]916413, N01-AG12100, N01-AG012100, AG027576, R01AR/AG 41398, AR/AG 41398, U01 AR45580, 263MD821336, U01-AG-18197, AG07181, N01-HC-25195, AG 024827, AG-6-2106, AG-6-2103, R01‐AR‐35584, R01AG018887, AG005394, U01AG018197, R01AG005407, R01 AR35583, U01 AR45632, U01AG027810, R01AG027576, P01AG023394, 916413, U01 AR45654, AG18197, R01AG007181, R01AG027087, U01 AR45614, AG-6-2101, AG028507, R01 AG18887, R01‐AR‐35582, U13 AG041583, N01AG62106, AG027574, U01 AR45583, AG027810, R01AG028507, U01 AR45647, AG41398, N01-AG-62103, R01AG027574, P30AG024827)
- National Heart, Lung, and Blood Institute (N01-HC-025195, P50HL105185)
- National Institute of Diabetes and Digestive and Kidney Diseases (N01-HC-25195, R01DK031801, DK-31801, AG07181)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01AR45614, R01 AR/AG 41398, R01-AR35582, U01-AR45632, N01-AG-12100, U01 AR45647, U01AR045583, R01AR035584, R01AR35583, U01 AR-45583, AR45654, AR45614, U01-AR-45654, AR45647, AR35583, U01AR045580, AR-35584, AR 35582, AR45583, U01AR045632, U01AR045654, R01AR035582, U01AR045614, AR45580, AR/AG 41398, U01AR045647, R01AR035583, U01 AG18197, AR45632, R01‐AR‐35584, U01AR45580)
- National Center for Research Resources (U01 AR45654, RR-06192, U01 AR45632, M01RR006192, MO1 RR06192, U01 AR45580, U01 AR45647, UL1RR024140, U01 AR45614, U01 AR45583, U01 AG18197, RR024140)
- National Institute on Minority Health and Health Disparities (R01MD009164)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
- Health Sciences › Medicine › Physiology (medical) › Body Composition Measurement Techniques
- Keywords
- sarcopenia, older adults, muscle weakness, appendicular lean mass, grip strength, body mass index, diagnostic criteria, cut-off values, community-dwelling older adults, biomarkers
- MeSH terms
- Age Factors, Aged, Aged, 80 and over, Disease Susceptibility, Female, Humans, Male, National Institutes of Health (U.S.), Research Design, Risk Factors, Sex Factors, United States, Body Mass Index, Hand Strength, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates. https://app.cochat.ai/papers/10.1093/gerona/glu010
- The paper
- Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., Kiel, D. P., Kritchevsky, S. B., Shardell, M. D., Dam, T.-T. L., & Vassileva, M. T. (2014). The FNIH Sarcopenia Project: Rationale, Study Description, Conference Recommendations, and Final Estimates. The Journals of Gerontology: Series A. https://doi.org/10.1093/gerona/glu010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
